We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for crisantaspase (PPD Australia Pty Ltd)
Active ingredients
crisantaspase
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
lyophilized powder for solution for injection/infusion
Indication
Indicated in combination with other chemotherapeutic agents to treat patients with paediatric acute lymphoblastic leukaemia (ALL)
Therapeutic area
Oncology